{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:37:37Z","timestamp":1785789457972,"version":"3.56.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":114,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","cmghjournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.jcmgh.2024.04.005","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T19:13:07Z","timestamp":1714504387000},"page":"101348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["RASSF4 Attenuates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression via Hippo Signaling and Suppresses Hepatocarcinogenesis"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8450-9119","authenticated-orcid":false,"given":"Chaofei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5682-2340","authenticated-orcid":false,"given":"Liming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmgh.2024.04.005_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib4","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib5","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2017.10.006","article-title":"Should we undertake surveillance for HCC in patients with NAFLD?","volume":"68","author":"Younes","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17050774","article-title":"The natural course of non-alcoholic fatty liver disease","volume":"17","author":"Calzadilla Bertot","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib9","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A\u00a0new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib11","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S2468-1253(22)00127-3","article-title":"Promoting the term MAFLD: China in action","volume":"7","author":"Zhang","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","article-title":"Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease","volume":"32","author":"Lim","year":"2021","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/0008-5472.CAN-17-1544","article-title":"Loss of RASSF4 expression in multiple myeloma promotes RAS-driven malignant progression","volume":"78","author":"De Smedt","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib14","doi-asserted-by":"crossref","first-page":"8688","DOI":"10.1158\/0008-5472.CAN-04-2065","article-title":"RASSF4\/AD037 is a potential ras effector\/tumor suppressor of the RASSF family","volume":"64","author":"Eckfeld","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib15","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1007\/s13277-015-4343-9","article-title":"RASSF4 is downregulated in nonsmall cell lung cancer and inhibits cancer cell proliferation and invasion","volume":"37","author":"Han","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib16","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1083\/jcb.201606047","article-title":"RASSF4 controls SOCE and ER-PM junctions through regulation of PI(4,5)P(2)","volume":"216","author":"Chen","year":"2017","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI67087","article-title":"Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression","volume":"124","author":"Crose","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1146\/annurev-pathol-030420-105050","article-title":"The Hippo pathway in liver homeostasis and pathophysiology","volume":"16","author":"Driskill","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The Hippo pathway: biology and pathophysiology","volume":"88","author":"Ma","year":"2019","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib20","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","article-title":"Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine","volume":"19","author":"Dey","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","article-title":"YAP\/TAZ signaling and resistance to cancer therapy","volume":"5","author":"Nguyen","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2019.05.029","article-title":"Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury","volume":"71","author":"Liu","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib23","article-title":"Sphingosine kinase 1\/S1P signaling contributes to pulmonary fibrosis by activating Hippo\/YAP pathway and mitochondrial reactive oxygen species in lung fibroblasts","volume":"21","author":"Huang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113674","article-title":"YAP\/TAZ signaling as a molecular link between fibrosis and cancer","volume":"19","author":"Noguchi","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jhep.2015.04.011","article-title":"The Hippo pathway effector YAP controls mouse hepatic stellate cell activation","volume":"63","author":"Mannaerts","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fnmol.2019.00220","article-title":"TIMP-1 attenuates the development of inflammatory pain through MMP-dependent and receptor-mediated cell signaling mechanisms","volume":"12","author":"Knight","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.769685","article-title":"Identification of molecular subtypes and a prognostic signature based on inflammation-related genes in colon adenocarcinoma","volume":"12","author":"Qiu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.886329","article-title":"Hypoxia- and inflammation-related transcription factor SP3 may be involved in platelet activation and inflammation in intracranial hemorrhage","volume":"13","author":"Wan","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH: current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib30","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/s42255-022-00642-5","article-title":"HK1 from hepatic stellate cell-derived extracellular vesicles promotes progression of hepatocellular carcinoma","volume":"4","author":"Chen","year":"2022","journal-title":"Nat Metab"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110349","article-title":"PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-\u03b2 receptor I versus II","volume":"38","author":"Sun","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib32","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1172\/JCI95802","article-title":"Hippo-mediated suppression of IRS2\/AKT signaling prevents hepatic steatosis and liver cancer","volume":"128","author":"Jeong","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib33","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.cmet.2016.09.016","article-title":"Hepatocyte TAZ\/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis","volume":"24","author":"Wang","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib34","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/hep.30928","article-title":"Hepatocyte stress increases expression of Yes-associated protein and transcriptional coactivator with PDZ-binding motif in hepatocytes to promote parenchymal inflammation and fibrosis","volume":"71","author":"Mooring","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib35","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/bph.13806","article-title":"The role of Hippo\/yes-associated protein signalling in vascular remodelling associated with cardiovascular disease","volume":"175","author":"He","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib36","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1111\/jcmm.14262","article-title":"A\u00a0functional interaction between Hippo-YAP signalling and SREBPs mediates hepatic steatosis in diabetic mice","volume":"23","author":"Shu","year":"2019","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrgastro.2013.244","article-title":"Liver: hepatic stellate cells hold the key to liver fibrosis","volume":"11","author":"Ray","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib38","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202201954R","article-title":"Liver sinusoidal endothelial S1pr2 regulates experimental liver fibrosis through YAP\/TGF-\u03b2 signaling pathway","volume":"37","author":"Liao","year":"2023","journal-title":"Faseb J"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib39","article-title":"LATS-YAP\/TAZ controls lineage specification by regulating TGF\u03b2 signaling and Hnf4\u03b1 expression during liver development","volume":"7","author":"Lee","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib40","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.devcel.2010.11.012","article-title":"The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-\u03b2-SMAD pathway","volume":"19","author":"Varelas","year":"2010","journal-title":"Dev Cell"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib41","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1016\/j.jmb.2015.04.015","article-title":"Crosstalk between Hippo and TGF\u03b2: subcellular localization of YAP\/TAZ\/Smad complexes","volume":"427","author":"Grannas","year":"2015","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153294","article-title":"Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-\u03b2\/Smad and YAP signaling","volume":"78","author":"Xiang","year":"2020","journal-title":"Phytomedicine"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib44","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1172\/JCI66369","article-title":"Hepatic stellate cells in liver development, regeneration, and cancer","volume":"123","author":"Yin","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1006\/cimm.2001.1800","article-title":"Costimulation by extracellular matrix proteins determines the response to TCR ligation","volume":"210","author":"Adler","year":"2001","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib46","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1083\/jcb.201102147","article-title":"The extracellular matrix: a dynamic niche in cancer progression","volume":"196","author":"Lu","year":"2012","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/labinvest.2013.139","article-title":"Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model","volume":"94","author":"Zhao","year":"2014","journal-title":"Lab Invest"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib48","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1158\/0008-5472.CAN-11-3317","article-title":"Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma","volume":"72","author":"Coulouarn","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib49","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","article-title":"The Hippo pathway and human cancer","volume":"13","author":"Harvey","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib50","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114351","article-title":"YAP\/TAZ and ATF4 drive resistance to sorafenib in hepatocellular carcinoma by preventing ferroptosis","volume":"13","author":"Gao","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib51","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.cub.2007.10.039","article-title":"YAP1 increases organ size and expands undifferentiated progenitor cells","volume":"17","author":"Camargo","year":"2007","journal-title":"Curr Biol"},{"key":"10.1016\/j.jcmgh.2024.04.005_bib52","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.aaw9886","article-title":"Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice","volume":"366","author":"Moya","year":"2019","journal-title":"Science"}],"container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X24000997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X24000997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T08:49:05Z","timestamp":1721206145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352345X24000997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2352345X24000997"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmgh.2024.04.005","relation":{},"ISSN":["2352-345X"],"issn-type":[{"value":"2352-345X","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RASSF4 Attenuates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression via Hippo Signaling and Suppresses Hepatocarcinogenesis","name":"articletitle","label":"Article Title"},{"value":"Cellular and Molecular Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmgh.2024.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}],"article-number":"101348"}}